Can a healthy adult use diphenhydramine as an over‑the‑counter sleep aid, and what dose and safety considerations apply?

Diphenhydramine for Sleep: Evidence-Based Recommendation

The American Academy of Sleep Medicine explicitly recommends AGAINST using diphenhydramine for insomnia in healthy adults, citing that the minimal sleep improvements (approximately 8 minutes shorter sleep latency and 12 minutes longer total sleep time) do not meet clinical significance thresholds and most well-informed patients would decline its use when presented with the evidence. 1, 2

Why Diphenhydramine Is Not Recommended

Minimal Clinical Benefit

• Meta-analysis of randomized controlled trials demonstrates that diphenhydramine reduces sleep latency by only 2.47 minutes compared to placebo (95% CI: −8.17 to +3.23 minutes), which falls far below the threshold for clinical significance. 1, 2

• Total sleep time increases by only 17.86 minutes versus placebo (95% CI: −3.79 to +39.51 minutes), which does not reach the AASM's predefined 20-minute threshold for meaningful improvement. 1, 2

• Polysomnography data—the objective gold standard—shows even smaller effects: 7.89 minutes reduction in sleep latency and 12.37 minutes increase in total sleep time. 1, 2

• The overall quality of evidence supporting diphenhydramine is rated as low due to imprecision, confidence intervals crossing clinical significance thresholds, and potential publication bias from industry-sponsored studies. 1

Significant Safety Concerns

• Diphenhydramine carries substantial anticholinergic burden causing daytime sedation, confusion (especially in older adults), urinary retention in men with benign prostatic hypertrophy, and increased fall risk. 1, 2, 3

• The 2015 Beers Criteria strongly recommend that adults ≥65 years avoid diphenhydramine entirely due to these anticholinergic effects. 4, 5

• Tolerance develops rapidly after only 3–4 days of continuous use, rendering the medication ineffective for ongoing sleep problems. 2

• The FDA label warns against use in patients with chronic bronchitis, glaucoma, or enlarged prostate, and cautions about marked drowsiness, impaired driving ability, and dangerous interactions with alcohol and sedatives. 3

Appropriate (But Limited) Use Scenarios

If Diphenhydramine Must Be Used

Diphenhydramine should only be considered for truly occasional, short-term insomnia (1–3 nights) when preferred alternatives are unavailable and the patient has no contraindications. 2, 3

• Dose: 25–50 mg orally at bedtime for adults and children over 12 years. 3

• Duration: Limit to 3–4 consecutive nights maximum due to rapid tolerance development. 2, 5

• Contraindications to screen for:

  • Age ≥65 years (Beers Criteria violation) 4, 5
  • Chronic bronchitis, asthma, or COPD 3
  • Glaucoma 3
  • Benign prostatic hypertrophy or urinary retention 3
  • Dementia or cognitive impairment 1, 2
  • Concurrent use of other sedatives, alcohol, or anticholinergic medications 3

• Patient counseling required:

  • Warn about next-day sedation and impaired driving ability 3, 5
  • Advise against alcohol consumption 3
  • Explain that benefits are minimal (8–12 minutes improvement) and tolerance develops quickly 2
  • Instruct to discontinue if no benefit after 2–3 nights 2

Superior Evidence-Based Alternatives

First-Line Non-Pharmacologic Treatment

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be initiated immediately for all adults with insomnia, demonstrating superior long-term efficacy compared to any medication and maintaining benefits after discontinuation. 1, 2, 6

Preferred Pharmacologic Options (When Medication Is Necessary)

The AASM issues weak recommendations FOR the following agents, all of which have more favorable benefit-to-harm profiles than diphenhydramine: 2, 6

For sleep-onset insomnia:

• Zaleplon 10 mg 2, 6
• Zolpidem 10 mg 2, 6
• Ramelteon 8 mg (preferred for patients with substance use history; no addiction potential) 2, 6
• Triazolam 0.25 mg 2, 6

For sleep-maintenance insomnia:

• Low-dose doxepin 3–6 mg (reduces wake-after-sleep-onset by 22–23 minutes with minimal side effects) 2, 6
• Eszopiclone 2–3 mg 2, 6
• Zolpidem 10 mg 2, 6
• Temazepam 15 mg 2, 6

For both sleep-onset and maintenance:

• Eszopiclone, zolpidem, or temazepam can address both patterns 6

Clinical Decision Algorithm

Step 1 – Patient Education:
Inform the patient that diphenhydramine provides only 8–12 minutes of sleep improvement, carries anticholinergic risks, and that most informed patients decline its use when presented with this evidence. 1, 2

Step 2 – Initiate CBT-I:
Start cognitive-behavioral therapy for insomnia immediately, including sleep hygiene education, stimulus control, sleep restriction, and relaxation techniques. 1, 2, 6

Step 3 – If Pharmacotherapy Is Needed:
Select one of the AASM weak-FOR alternatives based on the predominant insomnia pattern (sleep-onset vs. maintenance) rather than diphenhydramine. 2, 6

Step 4 – Conditional Diphenhydramine Use (Only If Absolutely Necessary):

• Verify no contraindications (age <65, no glaucoma, no BPH, no cognitive impairment, no respiratory disease) 3, 4
• Prescribe 25–50 mg at bedtime for maximum 3–4 nights 2, 3
• Document shared decision-making discussion and rationale 2
• Schedule follow-up within 1 week to reassess and transition to evidence-based alternatives 2

Common Pitfalls to Avoid

• Do not recommend diphenhydramine for chronic or recurrent insomnia—the AASM explicitly advises against this practice, and tolerance develops within days. 1, 2, 5

• Do not prescribe to older adults (≥65 years)—this violates Beers Criteria and significantly increases risk of falls, confusion, and cognitive impairment. 4, 5

• Do not assume OTC status equals safety—more than half of older adults inappropriately use diphenhydramine chronically (≥15 days/month), and many are unaware of safety risks. 4, 5

• Do not use diphenhydramine as a substitute for addressing underlying causes—screen for depression, anxiety, sleep apnea, medication side effects, and medical comorbidities that require specific treatment. 2